Antibiotic Incentives: Pfizer’s Read Touts Exclusivity Voucher

Providing a transferable period of patent-life extension in exchange for US FDA approval of a new antibiotic would incentivize ‘the whole ecosystem’ to find new treatments for emerging diseases, CEO Ian Read says.

Ian Read
• Source: Source: Courtesy of Noel St. John/National Press Club

Pfizer Inc. CEO Ian Read used his speech at the National Press Club to push for an old idea – a transferable exclusivity voucher program to incentivize antibiotic development.

Speaking March 23 in Washington, DC, Read was asked what can be done to encourage drug companies to develop vaccines...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access